泛素连接酶
受体酪氨酸激酶
计算生物学
细胞生物学
转录因子
蛋白质降解
泛素
小分子
药物发现
化学
生物
激酶
邻苯二甲酰亚胺
生物化学
基因
作者
Mette Ishoey,Someth Chorn,Natesh Singh,Martin G. Jaeger,Matthias Brand,Joshiawa Paulk,Sophie Bauer,Michael A. Erb,Katja Parapatics,André C. Müller,Keiryn L. Bennett,Gerhard F. Ecker,James E. Bradner,Georg E. Winter
标识
DOI:10.1021/acschembio.7b00969
摘要
Protein degradation is an emerging therapeutic strategy with a unique molecular pharmacology that enables the disruption of all functions associated with a target. This is particularly relevant for proteins depending on molecular scaffolding, such as transcription factors or receptor tyrosine kinases (RTKs). To address tractability of multiple RTKs for chemical degradation by the E3 ligase CUL4-RBX1-DDB1-CRBN (CRL4CRBN), we synthesized a series of phthalimide degraders based on the promiscuous kinase inhibitors sunitinib and PHA665752. While both series failed to induce degradation of their consensus targets, individual molecules displayed pronounced efficacy in leukemia cell lines. Orthogonal target identification supported by molecular docking led us to identify the translation termination factor G1 to S phase transition 1 (GSPT1) as a converging off-target, resulting from inadvertent E3 ligase modulation. This research highlights the importance of monitoring degradation events that are independent of the respective targeting ligand as a unique feature of small-molecule degraders.
科研通智能强力驱动
Strongly Powered by AbleSci AI